Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) Interest & Investment Income (2020 - 2025)

Avidity Biosciences (RNA) has disclosed Interest & Investment Income for 6 consecutive years, with $17.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest & Investment Income fell 3.66% year-over-year to $17.9 million, compared with a TTM value of $63.3 million through Dec 2025, up 11.2%, and an annual FY2025 reading of $63.3 million, up 11.2% over the prior year.
  • Interest & Investment Income was $17.9 million for Q4 2025 at Avidity Biosciences, up from $14.7 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $18.5 million in Q4 2024 and bottomed at $16000.0 in Q1 2021.
  • Average Interest & Investment Income over 5 years is $7.5 million, with a median of $6.0 million recorded in 2023.
  • The sharpest move saw Interest & Investment Income crashed 88.81% in 2021, then surged 7794.12% in 2022.
  • Year by year, Interest & Investment Income stood at $55000.0 in 2021, then skyrocketed by 4940.0% to $2.8 million in 2022, then soared by 131.06% to $6.4 million in 2023, then skyrocketed by 189.34% to $18.5 million in 2024, then fell by 3.66% to $17.9 million in 2025.
  • Business Quant data shows Interest & Investment Income for RNA at $17.9 million in Q4 2025, $14.7 million in Q3 2025, and $14.5 million in Q2 2025.